nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP1A2—chronic obstructive pulmonary disease	0.362	1	CbGaD
Nevirapine—CYP2A6—Arformoterol—chronic obstructive pulmonary disease	0.0793	0.158	CbGbCtD
Nevirapine—CYP2A6—Formoterol—chronic obstructive pulmonary disease	0.0793	0.158	CbGbCtD
Nevirapine—CYP2A6—Montelukast—chronic obstructive pulmonary disease	0.0601	0.12	CbGbCtD
Nevirapine—CYP2A6—Prednisolone—chronic obstructive pulmonary disease	0.0352	0.0703	CbGbCtD
Nevirapine—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0273	0.0544	CbGbCtD
Nevirapine—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0273	0.0544	CbGbCtD
Nevirapine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0257	0.0513	CbGbCtD
Nevirapine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0249	0.0497	CbGbCtD
Nevirapine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0249	0.0497	CbGbCtD
Nevirapine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0222	0.0443	CbGbCtD
Nevirapine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0209	0.0417	CbGbCtD
Nevirapine—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0207	0.0412	CbGbCtD
Nevirapine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0141	0.0282	CbGbCtD
Nevirapine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0135	0.0269	CbGbCtD
Nevirapine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.012	0.024	CbGbCtD
Nevirapine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00705	0.0141	CbGbCtD
Nevirapine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00666	0.0133	CbGbCtD
Nevirapine—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.000409	0.00406	CcSEcCtD
Nevirapine—Conjunctivitis—Arformoterol—chronic obstructive pulmonary disease	0.0004	0.00398	CcSEcCtD
Nevirapine—Conjunctivitis—Formoterol—chronic obstructive pulmonary disease	0.0004	0.00398	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.0004	0.00397	CcSEcCtD
Nevirapine—Neuropathy peripheral—Montelukast—chronic obstructive pulmonary disease	0.000395	0.00393	CcSEcCtD
Nevirapine—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.000393	0.00391	CcSEcCtD
Nevirapine—Jaundice—Montelukast—chronic obstructive pulmonary disease	0.000393	0.0039	CcSEcCtD
Nevirapine—Conjunctivitis—Montelukast—chronic obstructive pulmonary disease	0.000392	0.00389	CcSEcCtD
Nevirapine—Hepatobiliary disease—Montelukast—chronic obstructive pulmonary disease	0.000381	0.00379	CcSEcCtD
Nevirapine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000381	0.00379	CcSEcCtD
Nevirapine—Neuropathy peripheral—Salbutamol—chronic obstructive pulmonary disease	0.000381	0.00379	CcSEcCtD
Nevirapine—Jaundice—Salbutamol—chronic obstructive pulmonary disease	0.000379	0.00376	CcSEcCtD
Nevirapine—Conjunctivitis—Salbutamol—chronic obstructive pulmonary disease	0.000378	0.00375	CcSEcCtD
Nevirapine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000371	0.00369	CcSEcCtD
Nevirapine—Necrosis—Prednisone—chronic obstructive pulmonary disease	0.000369	0.00367	CcSEcCtD
Nevirapine—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000364	0.00362	CcSEcCtD
Nevirapine—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.000363	0.00361	CcSEcCtD
Nevirapine—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.000363	0.00361	CcSEcCtD
Nevirapine—Hepatitis—Montelukast—chronic obstructive pulmonary disease	0.000362	0.0036	CcSEcCtD
Nevirapine—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.000355	0.00353	CcSEcCtD
Nevirapine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000354	0.00352	CcSEcCtD
Nevirapine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000345	0.00343	CcSEcCtD
Nevirapine—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000343	0.00341	CcSEcCtD
Nevirapine—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.000342	0.0034	CcSEcCtD
Nevirapine—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000339	0.00337	CcSEcCtD
Nevirapine—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000339	0.00337	CcSEcCtD
Nevirapine—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000338	0.00336	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000337	0.00335	CcSEcCtD
Nevirapine—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000334	0.00332	CcSEcCtD
Nevirapine—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.000334	0.00332	CcSEcCtD
Nevirapine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000329	0.00327	CcSEcCtD
Nevirapine—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.000329	0.00327	CcSEcCtD
Nevirapine—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000327	0.00325	CcSEcCtD
Nevirapine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000326	0.00324	CcSEcCtD
Nevirapine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000326	0.00324	CcSEcCtD
Nevirapine—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000325	0.00323	CcSEcCtD
Nevirapine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000324	0.00322	CcSEcCtD
Nevirapine—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000319	0.00317	CcSEcCtD
Nevirapine—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000316	0.00314	CcSEcCtD
Nevirapine—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000315	0.00313	CcSEcCtD
Nevirapine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000307	0.00305	CcSEcCtD
Nevirapine—Ulcer—Prednisone—chronic obstructive pulmonary disease	0.000306	0.00304	CcSEcCtD
Nevirapine—Hypercholesterolaemia—Prednisone—chronic obstructive pulmonary disease	0.000306	0.00304	CcSEcCtD
Nevirapine—Dermatitis bullous—Prednisolone—chronic obstructive pulmonary disease	0.000303	0.00301	CcSEcCtD
Nevirapine—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.0003	0.00298	CcSEcCtD
Nevirapine—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000298	0.00297	CcSEcCtD
Nevirapine—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.00297	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000296	0.00294	CcSEcCtD
Nevirapine—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000294	0.00292	CcSEcCtD
Nevirapine—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000294	0.00292	CcSEcCtD
Nevirapine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000292	0.0029	CcSEcCtD
Nevirapine—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.00029	0.00288	CcSEcCtD
Nevirapine—Malaise—Formoterol—chronic obstructive pulmonary disease	0.00029	0.00288	CcSEcCtD
Nevirapine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000288	0.00286	CcSEcCtD
Nevirapine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000282	0.0028	CcSEcCtD
Nevirapine—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.0028	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000281	0.00279	CcSEcCtD
Nevirapine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00276	CcSEcCtD
Nevirapine—Skin exfoliation—Prednisone—chronic obstructive pulmonary disease	0.000276	0.00275	CcSEcCtD
Nevirapine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000274	0.00272	CcSEcCtD
Nevirapine—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000274	0.00272	CcSEcCtD
Nevirapine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000274	0.00272	CcSEcCtD
Nevirapine—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000274	0.00272	CcSEcCtD
Nevirapine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000274	0.00272	CcSEcCtD
Nevirapine—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000274	0.00272	CcSEcCtD
Nevirapine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000273	0.00271	CcSEcCtD
Nevirapine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000273	0.00271	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000272	0.0027	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000272	0.0027	CcSEcCtD
Nevirapine—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00027	0.00269	CcSEcCtD
Nevirapine—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.00269	CcSEcCtD
Nevirapine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000268	0.00267	CcSEcCtD
Nevirapine—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000268	0.00267	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000266	0.00265	CcSEcCtD
Nevirapine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000266	0.00264	CcSEcCtD
Nevirapine—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000262	0.00261	CcSEcCtD
Nevirapine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000262	0.00261	CcSEcCtD
Nevirapine—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000262	0.00261	CcSEcCtD
Nevirapine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000262	0.00261	CcSEcCtD
Nevirapine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.00257	CcSEcCtD
Nevirapine—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.00257	CcSEcCtD
Nevirapine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000258	0.00257	CcSEcCtD
Nevirapine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000257	0.00256	CcSEcCtD
Nevirapine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000257	0.00256	CcSEcCtD
Nevirapine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000257	0.00255	CcSEcCtD
Nevirapine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000257	0.00255	CcSEcCtD
Nevirapine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000257	0.00255	CcSEcCtD
Nevirapine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00254	CcSEcCtD
Nevirapine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000255	0.00253	CcSEcCtD
Nevirapine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000255	0.00253	CcSEcCtD
Nevirapine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000254	0.00252	CcSEcCtD
Nevirapine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000252	0.00251	CcSEcCtD
Nevirapine—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000252	0.0025	CcSEcCtD
Nevirapine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00025	0.00248	CcSEcCtD
Nevirapine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00246	CcSEcCtD
Nevirapine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00246	CcSEcCtD
Nevirapine—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000245	0.00244	CcSEcCtD
Nevirapine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000244	0.00242	CcSEcCtD
Nevirapine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000243	0.00242	CcSEcCtD
Nevirapine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000241	0.00239	CcSEcCtD
Nevirapine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00024	0.00238	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000239	0.00238	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000239	0.00238	CcSEcCtD
Nevirapine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00235	CcSEcCtD
Nevirapine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000236	0.00234	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000234	0.00233	CcSEcCtD
Nevirapine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000233	0.00232	CcSEcCtD
Nevirapine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000233	0.00232	CcSEcCtD
Nevirapine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000231	0.00229	CcSEcCtD
Nevirapine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00023	0.00229	CcSEcCtD
Nevirapine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000228	0.00227	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00225	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00225	CcSEcCtD
Nevirapine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000226	0.00225	CcSEcCtD
Nevirapine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000226	0.00225	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000226	0.00224	CcSEcCtD
Nevirapine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00223	CcSEcCtD
Nevirapine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00223	CcSEcCtD
Nevirapine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00221	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000222	0.00221	CcSEcCtD
Nevirapine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000222	0.0022	CcSEcCtD
Nevirapine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00219	CcSEcCtD
Nevirapine—Pain—Montelukast—chronic obstructive pulmonary disease	0.00022	0.00218	CcSEcCtD
Nevirapine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000219	0.00218	CcSEcCtD
Nevirapine—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000218	0.00217	CcSEcCtD
Nevirapine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000217	0.00216	CcSEcCtD
Nevirapine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000217	0.00216	CcSEcCtD
Nevirapine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000217	0.00215	CcSEcCtD
Nevirapine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.00215	CcSEcCtD
Nevirapine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000216	0.00215	CcSEcCtD
Nevirapine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000216	0.00215	CcSEcCtD
Nevirapine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00214	CcSEcCtD
Nevirapine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000215	0.00213	CcSEcCtD
Nevirapine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.00213	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00213	CcSEcCtD
Nevirapine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00212	CcSEcCtD
Nevirapine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.00211	CcSEcCtD
Nevirapine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00021	0.00209	CcSEcCtD
Nevirapine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000208	0.00207	CcSEcCtD
Nevirapine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000208	0.00207	CcSEcCtD
Nevirapine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00206	CcSEcCtD
Nevirapine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00206	CcSEcCtD
Nevirapine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00206	CcSEcCtD
Nevirapine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00206	CcSEcCtD
Nevirapine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000207	0.00205	CcSEcCtD
Nevirapine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000205	0.00204	CcSEcCtD
Nevirapine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000205	0.00204	CcSEcCtD
Nevirapine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000205	0.00204	CcSEcCtD
Nevirapine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000204	0.00203	CcSEcCtD
Nevirapine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00203	CcSEcCtD
Nevirapine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000204	0.00202	CcSEcCtD
Nevirapine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000203	0.00202	CcSEcCtD
Nevirapine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000203	0.00202	CcSEcCtD
Nevirapine—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000203	0.00202	CcSEcCtD
Nevirapine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00201	CcSEcCtD
Nevirapine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.00196	CcSEcCtD
Nevirapine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.00195	CcSEcCtD
Nevirapine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.00195	CcSEcCtD
Nevirapine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000193	0.00192	CcSEcCtD
Nevirapine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000193	0.00192	CcSEcCtD
Nevirapine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000193	0.00192	CcSEcCtD
Nevirapine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000189	0.00188	CcSEcCtD
Nevirapine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000188	0.00187	CcSEcCtD
Nevirapine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000188	0.00187	CcSEcCtD
Nevirapine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00185	CcSEcCtD
Nevirapine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00185	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000185	0.00184	CcSEcCtD
Nevirapine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000184	0.00183	CcSEcCtD
Nevirapine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.00181	CcSEcCtD
Nevirapine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00181	CcSEcCtD
Nevirapine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00178	CcSEcCtD
Nevirapine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00178	CcSEcCtD
Nevirapine—CYP3A5—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000179	0.00498	CbGpPWpGaD
Nevirapine—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000178	0.00177	CcSEcCtD
Nevirapine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00177	CcSEcCtD
Nevirapine—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000177	0.00494	CbGpPWpGaD
Nevirapine—CYP2B6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000176	0.00492	CbGpPWpGaD
Nevirapine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000176	0.00175	CcSEcCtD
Nevirapine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00174	CcSEcCtD
Nevirapine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000175	0.00487	CbGpPWpGaD
Nevirapine—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000174	0.00173	CcSEcCtD
Nevirapine—CYP3A5—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000172	0.00481	CbGpPWpGaD
Nevirapine—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000172	0.0048	CbGpPWpGaD
Nevirapine—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.00017	0.00169	CcSEcCtD
Nevirapine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.00017	0.00474	CbGpPWpGaD
Nevirapine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00169	CcSEcCtD
Nevirapine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000167	0.00166	CcSEcCtD
Nevirapine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.00166	CcSEcCtD
Nevirapine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00164	CcSEcCtD
Nevirapine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00164	CcSEcCtD
Nevirapine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00164	CcSEcCtD
Nevirapine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00164	CcSEcCtD
Nevirapine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000164	0.00163	CcSEcCtD
Nevirapine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000164	0.00163	CcSEcCtD
Nevirapine—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000164	0.00163	CcSEcCtD
Nevirapine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000163	0.00162	CcSEcCtD
Nevirapine—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000163	0.00455	CbGpPWpGaD
Nevirapine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000162	0.00161	CcSEcCtD
Nevirapine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000162	0.00161	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.00161	CcSEcCtD
Nevirapine—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000161	0.0045	CbGpPWpGaD
Nevirapine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000161	0.0016	CcSEcCtD
Nevirapine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000161	0.00449	CbGpPWpGaD
Nevirapine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.00158	CcSEcCtD
Nevirapine—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00158	CcSEcCtD
Nevirapine—CYP2A6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.00443	CbGpPWpGaD
Nevirapine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00157	CcSEcCtD
Nevirapine—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000157	0.00156	CcSEcCtD
Nevirapine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00155	CcSEcCtD
Nevirapine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00155	CcSEcCtD
Nevirapine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000156	0.00155	CcSEcCtD
Nevirapine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000156	0.00155	CcSEcCtD
Nevirapine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000155	0.00154	CcSEcCtD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000155	0.00432	CbGpPWpGaD
Nevirapine—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000154	0.00431	CbGpPWpGaD
Nevirapine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000153	0.00152	CcSEcCtD
Nevirapine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00146	CcSEcCtD
Nevirapine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000146	0.00146	CcSEcCtD
Nevirapine—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000146	0.00407	CbGpPWpGaD
Nevirapine—CYP2B6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.00404	CbGpPWpGaD
Nevirapine—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000143	0.00142	CcSEcCtD
Nevirapine—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000142	0.00397	CbGpPWpGaD
Nevirapine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.00141	CcSEcCtD
Nevirapine—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.00141	CcSEcCtD
Nevirapine—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000142	0.00396	CbGpPWpGaD
Nevirapine—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000141	0.00395	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000141	0.00394	CbGpPWpGaD
Nevirapine—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000137	0.00381	CbGpPWpGaD
Nevirapine—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000137	0.00381	CbGpPWpGaD
Nevirapine—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000131	0.00131	CcSEcCtD
Nevirapine—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00013	0.00364	CbGpPWpGaD
Nevirapine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.00013	0.00362	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000129	0.00361	CbGpPWpGaD
Nevirapine—CYP2B6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000128	0.00357	CbGpPWpGaD
Nevirapine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000128	0.00357	CbGpPWpGaD
Nevirapine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.00127	CcSEcCtD
Nevirapine—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000127	0.00354	CbGpPWpGaD
Nevirapine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000127	0.00354	CbGpPWpGaD
Nevirapine—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000127	0.00126	CcSEcCtD
Nevirapine—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000126	0.00351	CbGpPWpGaD
Nevirapine—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000125	0.00349	CbGpPWpGaD
Nevirapine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000124	0.00346	CbGpPWpGaD
Nevirapine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000123	0.00343	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000123	0.00342	CbGpPWpGaD
Nevirapine—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000122	0.00342	CbGpPWpGaD
Nevirapine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000122	0.00121	CcSEcCtD
Nevirapine—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000121	0.00339	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.00012	0.00335	CbGpPWpGaD
Nevirapine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000117	0.00117	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.00116	CcSEcCtD
Nevirapine—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000117	0.00116	CcSEcCtD
Nevirapine—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000116	0.00115	CcSEcCtD
Nevirapine—CYP2A6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000115	0.0032	CbGpPWpGaD
Nevirapine—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000114	0.00113	CcSEcCtD
Nevirapine—CYP2A6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000113	0.00316	CbGpPWpGaD
Nevirapine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.00112	CcSEcCtD
Nevirapine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000108	0.00107	CcSEcCtD
Nevirapine—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000108	0.00107	CcSEcCtD
Nevirapine—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000108	0.003	CbGpPWpGaD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000107	0.00106	CcSEcCtD
Nevirapine—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00106	CcSEcCtD
Nevirapine—CYP2B6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000105	0.00293	CbGpPWpGaD
Nevirapine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.00104	CcSEcCtD
Nevirapine—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000103	0.00289	CbGpPWpGaD
Nevirapine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000103	0.00103	CcSEcCtD
Nevirapine—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000103	0.00103	CcSEcCtD
Nevirapine—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000103	0.00287	CbGpPWpGaD
Nevirapine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000101	0.00101	CcSEcCtD
Nevirapine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000101	0.00281	CbGpPWpGaD
Nevirapine—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0001	0.0028	CbGpPWpGaD
Nevirapine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.0001	0.000997	CcSEcCtD
Nevirapine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	9.97e-05	0.00278	CbGpPWpGaD
Nevirapine—Anorexia—Prednisone—chronic obstructive pulmonary disease	9.84e-05	0.000978	CcSEcCtD
Nevirapine—CYP2A6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.53e-05	0.00266	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	9.45e-05	0.00264	CbGpPWpGaD
Nevirapine—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	9.45e-05	0.00264	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	9.45e-05	0.00264	CbGpPWpGaD
Nevirapine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	9.41e-05	0.000935	CcSEcCtD
Nevirapine—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	9.31e-05	0.0026	CbGpPWpGaD
Nevirapine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	9.27e-05	0.000922	CcSEcCtD
Nevirapine—CYP2B6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.25e-05	0.00258	CbGpPWpGaD
Nevirapine—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	9.2e-05	0.00257	CbGpPWpGaD
Nevirapine—CYP2A6—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	9.18e-05	0.00256	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.15e-05	0.00255	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	9.06e-05	0.00253	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.04e-05	0.00252	CbGpPWpGaD
Nevirapine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.02e-05	0.00252	CbGpPWpGaD
Nevirapine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	8.98e-05	0.000892	CcSEcCtD
Nevirapine—Rash—Prednisolone—chronic obstructive pulmonary disease	8.96e-05	0.000891	CcSEcCtD
Nevirapine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	8.95e-05	0.00089	CcSEcCtD
Nevirapine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	8.94e-05	0.00249	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.94e-05	0.00249	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	8.94e-05	0.00249	CbGpPWpGaD
Nevirapine—Fatigue—Prednisone—chronic obstructive pulmonary disease	8.9e-05	0.000885	CcSEcCtD
Nevirapine—Headache—Prednisolone—chronic obstructive pulmonary disease	8.9e-05	0.000885	CcSEcCtD
Nevirapine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	8.9e-05	0.00248	CbGpPWpGaD
Nevirapine—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	8.84e-05	0.00247	CbGpPWpGaD
Nevirapine—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	8.82e-05	0.00246	CbGpPWpGaD
Nevirapine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.51e-05	0.000846	CcSEcCtD
Nevirapine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	8.44e-05	0.000839	CcSEcCtD
Nevirapine—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.44e-05	0.000839	CcSEcCtD
Nevirapine—CYP2A6—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	8.33e-05	0.00232	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	8.3e-05	0.00232	CbGpPWpGaD
Nevirapine—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.2e-05	0.000815	CcSEcCtD
Nevirapine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.16e-05	0.000811	CcSEcCtD
Nevirapine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.16e-05	0.000811	CcSEcCtD
Nevirapine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	8.11e-05	0.00226	CbGpPWpGaD
Nevirapine—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	8.01e-05	0.00223	CbGpPWpGaD
Nevirapine—CYP2A6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.95e-05	0.00222	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	7.69e-05	0.00215	CbGpPWpGaD
Nevirapine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	7.64e-05	0.00213	CbGpPWpGaD
Nevirapine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.61e-05	0.000756	CcSEcCtD
Nevirapine—CYP2B6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	7.58e-05	0.00212	CbGpPWpGaD
Nevirapine—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7.54e-05	0.0021	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	7.52e-05	0.0021	CbGpPWpGaD
Nevirapine—CYP3A5—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	7.41e-05	0.00207	CbGpPWpGaD
Nevirapine—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.41e-05	0.000736	CcSEcCtD
Nevirapine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.31e-05	0.00204	CbGpPWpGaD
Nevirapine—Pruritus—Prednisone—chronic obstructive pulmonary disease	7.31e-05	0.000726	CcSEcCtD
Nevirapine—CYP2A6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.3e-05	0.00204	CbGpPWpGaD
Nevirapine—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	7.29e-05	0.00203	CbGpPWpGaD
Nevirapine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.25e-05	0.00202	CbGpPWpGaD
Nevirapine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	7.07e-05	0.000702	CcSEcCtD
Nevirapine—CYP2A6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.92e-05	0.00193	CbGpPWpGaD
Nevirapine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	6.58e-05	0.00184	CbGpPWpGaD
Nevirapine—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.57e-05	0.000653	CcSEcCtD
Nevirapine—Rash—Prednisone—chronic obstructive pulmonary disease	6.51e-05	0.000647	CcSEcCtD
Nevirapine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.51e-05	0.000647	CcSEcCtD
Nevirapine—Headache—Prednisone—chronic obstructive pulmonary disease	6.47e-05	0.000643	CcSEcCtD
Nevirapine—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	6.45e-05	0.0018	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.43e-05	0.00179	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.41e-05	0.00179	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.38e-05	0.00178	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.36e-05	0.00177	CbGpPWpGaD
Nevirapine—CYP2B6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.33e-05	0.00176	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.3e-05	0.00176	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.27e-05	0.00175	CbGpPWpGaD
Nevirapine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.19e-05	0.00173	CbGpPWpGaD
Nevirapine—CYP3A5—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.18e-05	0.00173	CbGpPWpGaD
Nevirapine—Nausea—Prednisone—chronic obstructive pulmonary disease	6.13e-05	0.00061	CcSEcCtD
Nevirapine—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	5.93e-05	0.00166	CbGpPWpGaD
Nevirapine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	5.9e-05	0.00165	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.89e-05	0.00164	CbGpPWpGaD
Nevirapine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	5.82e-05	0.00162	CbGpPWpGaD
Nevirapine—CYP2B6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.81e-05	0.00162	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.76e-05	0.00161	CbGpPWpGaD
Nevirapine—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.68e-05	0.00159	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.59e-05	0.00156	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—APIP—chronic obstructive pulmonary disease	5.57e-05	0.00155	CbGpPWpGaD
Nevirapine—CYP2B6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.51e-05	0.00154	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.46e-05	0.00152	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.45e-05	0.00152	CbGpPWpGaD
Nevirapine—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.39e-05	0.0015	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.38e-05	0.0015	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.34e-05	0.00149	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.3e-05	0.00148	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.27e-05	0.00147	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	5.23e-05	0.00146	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.23e-05	0.00146	CbGpPWpGaD
Nevirapine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	4.78e-05	0.00133	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—APIP—chronic obstructive pulmonary disease	4.49e-05	0.00125	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.48e-05	0.00125	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.46e-05	0.00124	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	4.43e-05	0.00124	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.42e-05	0.00123	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.4e-05	0.00123	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	4.39e-05	0.00123	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.36e-05	0.00122	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.2e-05	0.00117	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.16e-05	0.00116	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.1e-05	0.00114	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	4.06e-05	0.00113	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.06e-05	0.00113	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.04e-05	0.00113	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4e-05	0.00112	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	3.98e-05	0.00111	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	3.98e-05	0.00111	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.88e-05	0.00108	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.85e-05	0.00107	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.83e-05	0.00107	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.83e-05	0.00107	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.8e-05	0.00106	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	3.79e-05	0.00106	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	3.79e-05	0.00106	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.78e-05	0.00105	CbGpPWpGaD
Nevirapine—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.72e-05	0.00104	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.69e-05	0.00103	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GC—chronic obstructive pulmonary disease	3.59e-05	0.001	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.49e-05	0.000975	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.47e-05	0.000968	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.45e-05	0.000962	CbGpPWpGaD
Nevirapine—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.42e-05	0.000955	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.39e-05	0.000947	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.34e-05	0.000931	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.29e-05	0.000918	CbGpPWpGaD
Nevirapine—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.24e-05	0.000905	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.12e-05	0.000872	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	3.1e-05	0.000864	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.98e-05	0.000831	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.91e-05	0.000813	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.91e-05	0.000812	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GC—chronic obstructive pulmonary disease	2.9e-05	0.000808	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.87e-05	0.000802	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	2.83e-05	0.00079	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.69e-05	0.000751	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.68e-05	0.000747	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	2.65e-05	0.000738	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.64e-05	0.000737	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.63e-05	0.000734	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.54e-05	0.000708	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.5e-05	0.000699	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.21e-05	0.000616	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.07e-05	0.000577	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.05e-05	0.000572	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.04e-05	0.00057	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.03e-05	0.000568	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.01e-05	0.000562	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	2e-05	0.000557	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.96e-05	0.000547	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.94e-05	0.000541	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.89e-05	0.000527	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.87e-05	0.000522	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.86e-05	0.000518	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.77e-05	0.000494	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.75e-05	0.000489	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.71e-05	0.000476	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.63e-05	0.000455	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.59e-05	0.000442	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.58e-05	0.000442	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.56e-05	0.000436	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.55e-05	0.000432	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	1.53e-05	0.000427	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.48e-05	0.000412	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.43e-05	0.000398	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	1.4e-05	0.000389	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.36e-05	0.000379	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.35e-05	0.000378	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.34e-05	0.000374	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.32e-05	0.000367	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.31e-05	0.000367	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.29e-05	0.000359	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.26e-05	0.000352	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.25e-05	0.000349	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.22e-05	0.000341	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.18e-05	0.00033	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.1e-05	0.000307	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.1e-05	0.000306	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.09e-05	0.000304	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.09e-05	0.000303	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.08e-05	0.000302	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.08e-05	0.000301	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.07e-05	0.000299	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.06e-05	0.000295	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.01e-05	0.000281	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1e-05	0.00028	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	9.92e-06	0.000277	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.85e-06	0.000275	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	9.83e-06	0.000274	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.55e-06	0.000267	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.34e-06	0.000261	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.32e-06	0.00026	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	9.21e-06	0.000257	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.14e-06	0.000255	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.06e-06	0.000253	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.59e-06	0.00024	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	8.4e-06	0.000234	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ALB—chronic obstructive pulmonary disease	8.05e-06	0.000225	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—NOS3—chronic obstructive pulmonary disease	7.7e-06	0.000215	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.62e-06	0.000213	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.56e-06	0.000211	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.52e-06	0.00021	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.45e-06	0.000208	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.19e-06	0.000201	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	7.11e-06	0.000198	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	7e-06	0.000195	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.94e-06	0.000194	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.64e-06	0.000185	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.58e-06	0.000184	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ALB—chronic obstructive pulmonary disease	6.49e-06	0.000181	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	6.49e-06	0.000181	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.46e-06	0.00018	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.37e-06	0.000178	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	6.35e-06	0.000177	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NOS3—chronic obstructive pulmonary disease	6.21e-06	0.000173	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	6.07e-06	0.000169	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.98e-06	0.000167	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.93e-06	0.000166	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.63e-06	0.000157	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.98e-06	0.000139	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.92e-06	0.000137	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.58e-06	0.000128	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.51e-06	0.000126	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	4.47e-06	0.000125	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.34e-06	0.000121	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.32e-06	0.00012	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	4.28e-06	0.000119	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	3.82e-06	0.000107	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.66e-06	0.000102	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.95e-06	8.24e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.82e-06	7.88e-05	CbGpPWpGaD
